Literature DB >> 7644104

Starting r-HuEPO in chronic renal failure: when, why, and how?

R A Koene1, L A Frenken.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7644104     DOI： 10.1093/ndt/10.supp2.35

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  2 in total

1.  Subcutaneous r-HuEPO therapy in CAPD patients: dose determination and clinical experience.

Authors:  L Janicka; A Ksiazek; I Baranowicz; A Bednarek-Skublewska; P Mierzicki; P Ksiazek
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 2.  Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure.

Authors:  C J Dunn; A Markham
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.